146 related articles for article (PubMed ID: 27651692)
1. Discordance of Estrogen & Progesterone Receptors After Neoadjuvant Chemotherapy in Breast Cancer- an Indian Study.
Anand AS; Velayudhan ST
Indian J Surg Oncol; 2016 Sep; 7(3):316-9. PubMed ID: 27651692
[TBL] [Abstract][Full Text] [Related]
2. Discordance of estrogen and progesterone receptors after neoadjuvant chemotherapy in locally advanced breast cancer.
Gupta S; Anto A; Singhal J; Agarwal P
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147956
[TBL] [Abstract][Full Text] [Related]
3. Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer.
Basak Oven Ustaalioglu B; Aker Vardar F; Bilici A; Gurleyik G; Erkol B; Kefeli U; Aliustaoglu M
J BUON; 2014; 19(4):879-86. PubMed ID: 25536590
[TBL] [Abstract][Full Text] [Related]
4. Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer - a Single Centre Study. (PPLB - 01).
Agrawal S; Banswal L; Saha A; Arun I; Datta SS; Chatterjee S; Ahmed R
Indian J Surg Oncol; 2016 Dec; 7(4):397-406. PubMed ID: 27872526
[TBL] [Abstract][Full Text] [Related]
5. Alteration in steroid hormone and Her-2/neu receptor status following neoadjuvant chemotherapy in locally advanced breast cancer: Experience at a tertiary care centre in India.
Ramteke P; Seenu V; Prashad R; Gupta SD; Iyer V; Deo S; Gogia A; Mathur S
Indian J Cancer; 2016; 53(3):366-371. PubMed ID: 28244460
[TBL] [Abstract][Full Text] [Related]
6. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.
Berghuis AMS; van Deurzen CHM; Koffijberg H; Terstappen LWMM; Sleijfer S; IJzerman MJ
Breast Cancer Res Treat; 2019 Jun; 175(2):451-458. PubMed ID: 30756285
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
9. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
11. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer.
Ding Y; Ding K; Qian H; Yu X; Zou D; Yang H; Mo W; He X; Zhang F; Qin C; Zheng Y; Ding X
PLoS One; 2020; 15(4):e0231895. PubMed ID: 32298374
[TBL] [Abstract][Full Text] [Related]
12. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
Gahlaut R; Bennett A; Fatayer H; Dall BJ; Sharma N; Velikova G; Perren T; Dodwell D; Lansdown M; Shaaban AM
Eur J Cancer; 2016 Jun; 60():40-8. PubMed ID: 27062316
[TBL] [Abstract][Full Text] [Related]
13. [Association between hormone receptors and response to neoadjuvant anthracycline-based chemotherapy in breast cancer patients].
Wei Y; Li JF; Wang TF; Xie YT; Fan ZQ; Fan T; Lu AP; Ouyang T; Lin BY
Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Oct; 39(5):481-3. PubMed ID: 17940564
[TBL] [Abstract][Full Text] [Related]
14. Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki-67 in Chinese breast cancer patients: A retrospective study of 525 patients.
Wu YT; Li X; Lu LJ; Gan L; Dai W; Shi YL; Adhikari VP; Wu KN; Kong LQ
J Biomed Res; 2017 Nov; 32(3):191-7. PubMed ID: 29770779
[TBL] [Abstract][Full Text] [Related]
15. Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.
Trifunovic J; Memisevic N; Nikolin B; Salma S; Dugandzija T; Vidovic V
J BUON; 2017; 22(2):638-643. PubMed ID: 28730768
[TBL] [Abstract][Full Text] [Related]
16. Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
Chatterjee S; Saha A; Arun I; Nayak SS; Sinha S; Agrawal S; Parihar M; Ahmed R
Breast Cancer (Dove Med Press); 2015; 7():381-8. PubMed ID: 26677343
[TBL] [Abstract][Full Text] [Related]
17. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
Niikura N; Tomotaki A; Miyata H; Iwamoto T; Kawai M; Anan K; Hayashi N; Aogi K; Ishida T; Masuoka H; Iijima K; Masuda S; Tsugawa K; Kinoshita T; Nakamura S; Tokuda Y
Ann Oncol; 2016 Mar; 27(3):480-7. PubMed ID: 26704052
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
Precht LM; Lowe KA; Atwood M; Beatty JD
Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Receptor Change After Neoadjuvant Chemotherapy in Breast Cancer Patients.
Özdemir Ö; Zengel B; Kocatepe Çavdar D; Yılmaz C; Durusoy R
Eur J Breast Health; 2022 Apr; 18(2):167-171. PubMed ID: 35445177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
